Literature DB >> 4086603

High-performance liquid chromatographic determination of diltiazem and four of its metabolites in plasma. Application to pharmacokinetics.

K J Goebel, E U Kölle.   

Abstract

A selective and very sensitive ion-pairing reversed-phase high-performance liquid chromatographic method has been developed for the simultaneous determination of diltiazem and four of its metabolites in plasma. The structurally related compound propionyl deacetyl-diltiazem was used as the internal standard and bromide was employed as the pairing ion. Plasma samples were extracted with methyl-tert.-butyl ether followed by back-extraction into 0.01 M hydrochloric acid and evaporation to dryness. High-performance liquid chromatographic analysis was carried out using C18-bonded silica and methanol-ammonium bromide-acetonitrile-triethylamine as the mobile phase. Using UV detection at 237 nm, the lower limit of detection in plasma was 0.1-0.2 ng/ml; calibration curves were linear between 1 and 800 ng/ml. The present assay procedure has been applied to monitoring plasma levels in intravenous and oral pharmacokinetic studies in several animal species and humans. The applicability of the new method could be confirmed by comparing plasma levels obtained by high-performance liquid chromatography with those obtained by gas chromatography.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4086603     DOI: 10.1016/0378-4347(85)80172-9

Source DB:  PubMed          Journal:  J Chromatogr


  7 in total

1.  Performance of diltiazem tablet and multiparticulate osmotic formulations in the dog.

Authors:  S C Sutton; K Engle; R A Deeken; K E Plute; R D Shaffer
Journal:  Pharm Res       Date:  1990-08       Impact factor: 4.200

Review 2.  Diltiazem. A reappraisal of its pharmacological properties and therapeutic use.

Authors:  M M Buckley; S M Grant; K L Goa; D McTavish; E M Sorkin
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

3.  Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.

Authors:  Christopher Louizos; Jaime A Yáñez; M Laird Forrest; Neal M Davies
Journal:  J Pharm Pharm Sci       Date:  2014       Impact factor: 2.327

Review 4.  Clinical pharmacokinetics of verapamil, nifedipine and diltiazem.

Authors:  H Echizen; M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

5.  Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, diltiazem, and sparteine.

Authors:  F Wagner; E Jähnchen; D Trenk; M Eichelbaum; P Harnasch; G Hauf; H Roskamm
Journal:  Klin Wochenschr       Date:  1987-12-15

6.  Decreased systemic clearance of diltiazem with increased hepatic metabolism in rats with uranyl nitrate-induced acute renal failure.

Authors:  Y H Lee; M H Lee; C K Shim
Journal:  Pharm Res       Date:  1992-12       Impact factor: 4.200

7.  Pharmacokinetics and metabolism of diltiazem in healthy males and females following a single oral dose.

Authors:  P K Yeung; C Prescott; C Haddad; T J Montague; C McGregor; M A Quilliam; M Xei; R Li; P Farmer; G A Klassen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Apr-Jun       Impact factor: 2.441

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.